X4 Pharmaceuticals, Inc. (XFOR) Return on equity 2019–2025
X4 Pharmaceuticals, Inc. (XFOR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-42.5%FY2025 · since FY2019: -40.9% → -42.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -42.5% | +126.6 pp |
| FY2024 | -169.1% | +28.9 pp |
| FY2023 | -198.0% | -71.2 pp |
| FY2022 | -126.8% | +10.9 pp |
| FY2021 | -137.7% | -52.4 pp |
| FY2020 | -85.3% | -44.5 pp |
| FY2019 | -40.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice